Filing Flows › Rhythm Pharmaceuticals (RYTM) › Stock forecast & fair value
Rhythm Pharmaceuticals (RYTM) stock forecast and price target
Rhythm Pharmaceuticals (RYTM) trades at $112.28. 17 analysts' median price target is $143.00 (+27%), from $112.00 to $166.00.
Rhythm Pharmaceuticals' latest quarter
Rhythm Pharmaceuticals, Q3 2026: revenue $92.1M (+80% year over year), operating margin -42.6%, net loss $41.4M, operating cash flow −$3.1M. The chart follows the revenue to costs, profit and cash.
Questions
What is the price target for RYTM stock?
The median of 17 analysts' 12-month targets is $143.00, +27% from $112.28; the range is $112.00 to $166.00. The average rating is strong buy.
Does Rhythm Pharmaceuticals usually beat earnings estimates?
It beat the consensus EPS estimate in 80% of the quarters on record.
Is RYTM stock a buy?
Filing Flows does not give advice. It shows what analysts expect, what each valuation method implies and the figures behind them, read from SEC filings, so you can judge for yourself.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.